{{Drugbox
| IUPAC_name = (2''E'')-2-(fluoromethylidene)-4-(4-fluorophenyl)butan-1-amine
| image = Mofegiline.svg
| CAS_number = 119386-96-8
| ATC_prefix = None
| ATC_suffix = 
| UNII = 1FMJ6D8Y1B
| PubChem = 6437850
| ChemSpiderID = 4942371
| C = 11 | H = 13 | F = 2 | N = 1
| molecular_weight = 197.224 g/mol
| smiles = Fc1ccc(cc1)CCC(=[C@H]F)CN
| synonyms = MDL-72,974A
| StdInChI = 1S/C11H13F2N/c12-7-10(8-14)2-1-9-3-5-11(13)6-4-9/h3-7H,1-2,8,14H2/b10-7+
| StdInChIKey = VXLBSYHAEKDUSU-JXMROGBWSA-N
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 1–3 hours<ref name="pmid7554709">{{cite journal | vauthors = Stoltz M, Reynolds D, Elkins L, Salazar D, Weir S | title = Pharmacokinetics and pharmacodynamics of the monoamine oxidase B inhibitor mofegiline assessed during a phase I dose tolerance trial | journal = Clinical Pharmacology and Therapeutics | volume = 58 | issue = 3 | pages = 342–53 |date=September 1995 | pmid = 7554709 | doi = 10.1016/0009-9236(95)90252-X }}</ref>
| excretion = Urine<ref name="pmid8489556">{{cite journal  |vauthors=Dulery BD, Schoun J, Zreika M, etal | title = Pharmacokinetics of and monoamine oxidase B inhibition by (E)-4-fluoro-beta-fluoromethylene benzene butanamine in man | journal = Arzneimittel-Forschung | volume = 43 | issue = 3 | pages = 297–302 |date=March 1993 | pmid = 8489556 | doi = | url = }}</ref>
| pregnancy_category = 
| legal_status = Development terminated
| routes_of_administration = Oral<ref name="pmid7554709"/>
}}

'''Mofegiline''' ('''MDL-72,974''') is a [[binding selectivity|selective]], [[enzyme inhibitor#Irreversible inhibitors|irreversible]] [[enzyme inhibitor|inhibitor]] of [[monoamine oxidase B]] (MAO-B) and [[semicarbazide-sensitive amine oxidase]] (SSAO) which was under investigation for the treatment of [[Parkinson's disease]] and [[Alzheimer's disease]],<ref name="pmid3266532">{{cite journal | vauthors = Palfreyman MG, McDonald IA, Bey P, Schechter PJ, Sjoerdsma A | title = Design and early clinical evaluation of selective inhibitors of monoamine oxidase | journal = Progress in Neuro-psychopharmacology & Biological Psychiatry | volume = 12 | issue = 6 | pages = 967–87 | year = 1988 | pmid = 3266532 | doi = 10.1016/0278-5846(88)90092-9| url = }}</ref><ref name="pmid2597310">{{cite journal | vauthors = Zreika M, Fozard JR, Dudley MW, Bey P, McDonald IA, Palfreyman MG | title = MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease | journal = Journal of Neural Transmission. Parkinson's Disease and Dementia Section | volume = 1 | issue = 4 | pages = 243–54 | year = 1989 | pmid = 2597310 | doi = 10.1007/bf02263478| url = }}</ref><ref name="pmid7931257">{{cite journal | vauthors = Palfreyman MG, McDonald IA, Bey P, Danzin C, Zreika M, Cremer G | title = Haloallylamine inhibitors of MAO and SSAO and their therapeutic potential | journal = Journal of Neural Transmission. Supplementum | volume = 41 | issue = | pages = 407–14 | year = 1994 | pmid = 7931257 | doi = 10.1007/978-3-7091-9324-2_54| url = | isbn = 978-3-211-82521-1 }}</ref><ref name="pmid9488505">{{cite journal | vauthors = Thiffault C, Quirion R, Poirier J | title = Effect of the MAO-B inhibitor, MDL72974, on superoxide dismutase activity and lipid peroxidation levels in the mouse brain | journal = Synapse | volume = 28 | issue = 3 | pages = 208–11 |date=March 1998 | pmid = 9488505 | doi = 10.1002/(SICI)1098-2396(199803)28:3<208::AID-SYN3>3.0.CO;2-E | url = }}</ref> but was never marketed.<ref name="GanellinTriggle1997">{{ cite book | author1 = Ganellin, C. R. | author2 = Triggle, D. J. | author3 = Macdonald, F. | title = Dictionary of pharmacological agents | url = https://books.google.com/books?id=A0THacd46ZsC&pg=PA1370 | accessdate = 25 November 2011 | year = 1997 | publisher = CRC Press | isbn = 978-0-412-46630-4 | page = 1370 }}</ref>

== See also ==
* [[Ladostigil]]
* [[Lazabemide]]
* [[Rasagiline]]
* [[Selegiline]]

== References ==
{{Reflist}}

{{Antioxidants}}
{{Antidementia}}
{{Antiparkinson}}
{{Monoamine metabolism modulators}}

[[Category:Abandoned drugs]]
[[Category:Antidementia agents]]
[[Category:Antiparkinsonian agents]]
[[Category:Monoamine oxidase inhibitors]]